KTTA (Pasithea Therapeutics) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pasithea Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pasithea Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-2.44 Mil. Pasithea Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Pasithea Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Pasithea Therapeutics's current FCF Yield % is -405.21%.

The historical rank and industry rank for Pasithea Therapeutics's FCF Margin % or its related term are showing as below:

During the past 5 years, the highest FCF Margin % of Pasithea Therapeutics was -21306.67%. The lowest was -21306.67%. And the median was -21306.67%.

KTTA's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -127.825
* Ranked among companies with meaningful FCF Margin % only.

Pasithea Therapeutics FCF Margin % Historical Data

The historical data trend for Pasithea Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pasithea Therapeutics FCF Margin % Chart

Pasithea Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

-21,306.67

Pasithea Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Pasithea Therapeutics's FCF Margin %

For the Biotechnology subindustry, Pasithea Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pasithea Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Pasithea Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Pasithea Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Pasithea Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-13.923	/	0
	=	%

Pasithea Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-2.443	/	0
	=	%

Pasithea Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Pasithea Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pasithea Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pasithea Therapeutics Corp (NAS:KTTA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139

Website

https://www.pasithea.com

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.

Executives

Graeme Martin Currie	officer: Chief Development Officer	51 BARBAREE WAY, TIBURON CA 94920
Lawrence Steinman	director	10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Bradford Manning	10 percent owner	C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Paul B Manning	10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Tiger Lily Capital, Llc	10 percent owner	C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Pd Joint Holdings, Llc Series 2016-a	10 percent owner	C/O TIGER LILY CAPITAL LLC, 200 GARRETT STREET, SUITE O, CHARLOTTESVILLE VA 22902
Elderhill Corp	other: Member of 10% owner group	C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T IN5
Concord Ip2 Ltd.	other: Member of 10% owner group	C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
David Delaney	other: Member of 10% owner group	C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
Eric Shahinian	other: Member of 10% owner group	350 PARK AVE, 13TH FL, NEW YORK NY 10022
Alfred J Novak	director	325 NE 6TH ST, BOCA RATON FL 33432
Camac Partners, Llc	other: Member of 10% owner group	350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Capital, Llc	other: Member of 10% owner group	350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Fund, Lp	other: Member of 10% owner group	CAMAC CAPITAL, LLC, 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Leonite Capital Llc	other: Member of 10% owner group	1 HILLCREST CENTER DR., SUITE 232, SPRING VALLEY NY 10977